HOME >> BIOLOGY >> NEWS
Results of world's first gene therapy trial for arthritis show approach safe, feasible

PITTSBURGH, June 6 Gene therapy for arthritis and other non-terminal, debilitating conditions and diseases is both feasible and safe, report researchers who conducted the world's first such test on the approach in patients with advanced rheumatoid arthritis. The results, published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS), indicate that introducing a new gene has the potential to block the destructive inflammation process that takes place within arthritic joints. At a time when setbacks have cast doubt on the future of gene therapy, the results also provide assurance that it can be performed without causing undue harm to patients.

The clinical trial, which was conducted at the University of Pittsburgh School of Medicine between 1996 and 1999, involved nine women who had genetically modified cells injected into their arthritic knuckles and marked the first time a gene was introduced into a human joint. The researchers say their results showing that successful gene transfer can target joint inflammation open the door to the development of improved gene-based therapies for both rheumatoid and the more common osteoarthritis, which together affect about 66 million people in the United States. While the Pitt study used the same vector an inactivated virus that shuttles a gene into cells as a more recent French trial for X-linked severe combined immunodeficiency (X-SCID) in which three children later developed leukemia, the researchers point out that this is the only similarity between the two trials. The studies were concerned with different genes and with different targets, and in the arthritis trial, the transduced cells were removed after one week during routine joint replacement surgery. Nonetheless, with safety a key concern, the authors report no clinical side effects up to five years after the procedure and no evidence that the vector, a replication-defective retrovirus called Maloney Murine Leukemia Viru
'"/>


6-Jun-2005


Page: 1 2 3 4

Related biology news :

1. Combating anthrax: Results of study published this month as researchers look for a better vaccine
2. NASA-funded robotic sub finds bottom of worlds deepest sinkhole
3. Genome of Clostridium botulinum reveals the background to worlds deadliest toxin
4. Journal details how global warming will affect the worlds fisheries
5. NASA mission explores worlds deepest sinkhole
6. 20 of worlds 162 grouper species threatened with extinction
7. Failure to meet United Nations sanitation target could affect millions of the worlds poorest
8. Are we killing the worlds oceans?
9. LIAI completes worlds most comprehensive analysis on influenza virus data
10. Thorium poised to meet worlds energy needs
11. NCI funds Einstein and U. Albany NanoCollege to make worlds smallest cancer detection device

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... Catalent, the leading ... cell and gene therapies, and consumer health products, today announced that two Catalent ... & Expo, taking place between Aug. 31 – September 4, 2020. , On ...
(Date:8/21/2020)... (PRWEB) , ... August 19, 2020 , ... ... Salimetrics LLC and SalivaBio LLC, businesses dedicated to Salivary Bioscience for more than ... the recently published book by Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva ...
(Date:8/12/2020)... ... August 12, 2020 , ... Mosio ... are ideal for public health agencies of all sizes. With a focus on ... at-risk individuals find appropriate health care, Mosio helps public health departments automate communications ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... August 03, 2020 , ... ... Corrigan, President and CEO has been named one of the 100 most inspiring ... sectors, PharmaVoice 100 honorees are selected based on how they have inspired their ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... can combine up to three different materials for use with CRM, neurostimulation, vascular, ... to three materials to meet specific design requirements, performance, and cost criteria; especially ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed Tech , ... Solutions, in a one hour live webinar on Thursday, August 13, 2020 ... for drugs and medical devices. Specifically, for medical devices, the NMPA has departments dealing ...
(Date:7/10/2020)... ... July 08, 2020 , ... ... a significant expansion of laboratory operations through its COVID-19 testing service, Bode-CARES ... programs. , Bode-CARES provides a turnkey solution that includes a ...
Breaking Biology Technology:
Cached News: